COMMUNIQUÉS West-GlobeNewswire
-
Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma
03/03/2026 -
Prenetics Executives Execute Second Consecutive Round of Post-Earnings Open Market Share Purchases of $1.3 Million— Cumulative Personal Investment Across Both Rounds Reaches $2.7 Million
03/03/2026 -
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
03/03/2026 -
Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share
03/03/2026 -
COUR Pharma Announces Positive One-Year Results from the Phase 2a Study of CNP-104 in Primary Biliary Cholangitis
03/03/2026 -
BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT)
03/03/2026 -
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
03/03/2026 -
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference
03/03/2026 -
Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission
03/03/2026 -
Opus Genetics to Present at Upcoming Investor Conferences in March 2026
03/03/2026 -
NDT Pharmaceuticals Highlights Enhanced Omni-Channel Positioning; Sets Stage for 2026 Growth with Strategic Marketing Expansion
03/03/2026 -
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates
03/03/2026 -
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences
03/03/2026 -
Chiesi Global Rare Diseases Announces FDA Approval of JUXTAPID® (lomitapide) Capsules for Pediatric Use in Homozygous Familial Hypercholesterolemia (HoFH)
03/03/2026 -
Fort Wayne Rheumatologists Monica Reddy, Karen Ringwald and Anil Rao Open Fort Wayne Rheumatology and Infusion
03/03/2026 -
Cirrus Therapeutics Announces Strategic Expansion to Singapore and Other Key Updates Supporting its Growth as a Leading Global Ocular Immunology Company
03/03/2026 -
Quell Therapeutics Initiates CHILL Phase 1/2 Trial of Novel QEL-005 CAR-Treg Therapy in Refractory Rheumatoid Arthritis and Systemic Sclerosis Following UK CTA Approval
03/03/2026 -
Resmed’s Global Sleep Survey Reveals Sleep is One of the Top Health Priorities, but Quality Rest Remains Out of Reach
03/03/2026 -
SHERPA research consortium initiates seven clinical studies to validate AI-based assistive technologies for minimally invasive brain and cancer treatments
03/03/2026
Pages